CN102325823B - 得到改性聚乙二醇中间体的合成 - Google Patents

得到改性聚乙二醇中间体的合成 Download PDF

Info

Publication number
CN102325823B
CN102325823B CN200980157390.0A CN200980157390A CN102325823B CN 102325823 B CN102325823 B CN 102325823B CN 200980157390 A CN200980157390 A CN 200980157390A CN 102325823 B CN102325823 B CN 102325823B
Authority
CN
China
Prior art keywords
synthesis
mixture
linkers
linker
boc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN200980157390.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN102325823A (zh
Inventor
T·恩格尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare Ltd
Original Assignee
GE Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GE Healthcare Ltd filed Critical GE Healthcare Ltd
Publication of CN102325823A publication Critical patent/CN102325823A/zh
Application granted granted Critical
Publication of CN102325823B publication Critical patent/CN102325823B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/331—Polymers modified by chemical after-treatment with organic compounds containing oxygen
    • C08G65/332—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof
    • C08G65/3324—Polymers modified by chemical after-treatment with organic compounds containing oxygen containing carboxyl groups, or halides, or esters thereof cyclic
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G65/00—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule
    • C08G65/02—Macromolecular compounds obtained by reactions forming an ether link in the main chain of the macromolecule from cyclic ethers by opening of the heterocyclic ring
    • C08G65/32—Polymers modified by chemical after-treatment
    • C08G65/329—Polymers modified by chemical after-treatment with organic compounds
    • C08G65/333—Polymers modified by chemical after-treatment with organic compounds containing nitrogen
    • C08G65/33331—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing imide group
    • C08G65/33337—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing imide group cyclic
    • C08G65/33341—Polymers modified by chemical after-treatment with organic compounds containing nitrogen containing imide group cyclic aromatic
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L2203/00—Applications
    • C08L2203/02—Applications for biomedical use

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Polymers & Plastics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Polyethers (AREA)
CN200980157390.0A 2008-12-22 2009-12-07 得到改性聚乙二醇中间体的合成 Expired - Fee Related CN102325823B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13968908P 2008-12-22 2008-12-22
US61/139689 2008-12-22
PCT/US2009/066917 WO2010074935A1 (en) 2008-12-22 2009-12-07 Synthesis of obtaining modified polyethylene glycol intermediates

Publications (2)

Publication Number Publication Date
CN102325823A CN102325823A (zh) 2012-01-18
CN102325823B true CN102325823B (zh) 2014-02-26

Family

ID=41818624

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980157390.0A Expired - Fee Related CN102325823B (zh) 2008-12-22 2009-12-07 得到改性聚乙二醇中间体的合成

Country Status (5)

Country Link
US (1) US8536375B2 (https=)
EP (1) EP2370501A1 (https=)
JP (1) JP2012513391A (https=)
CN (1) CN102325823B (https=)
WO (1) WO2010074935A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112020008540A2 (pt) 2017-11-06 2020-10-06 Hanmi Fine Chemical Co., Ltd. derivado de polietilenoglicol e método de preparação deste
IL281212B2 (en) 2018-09-07 2023-12-01 Merck Patent Gmbh 5-Morpholin-4-yl-pyrazolo[4,3-B]pyridine derivatives and their use

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016221A1 (en) * 1991-03-15 1992-10-01 Synergen, Inc. Pegylation of polypeptides
CN1882693A (zh) * 2003-09-15 2006-12-20 普洛体维生物治疗公司 聚乙二醇修饰的脂质化合物及其应用

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6858409B1 (en) 1988-05-27 2005-02-22 Amgen Inc. Nucleic acids encoding interleukin-1 inhibitors and processes for preparing interleukin-1 inhibitors
WO2009108484A1 (en) 2008-02-28 2009-09-03 Ge Healthcare Limited Synthesis of a peg-6 moiety from commercial low-cost chemicals

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992016221A1 (en) * 1991-03-15 1992-10-01 Synergen, Inc. Pegylation of polypeptides
CN1882693A (zh) * 2003-09-15 2006-12-20 普洛体维生物治疗公司 聚乙二醇修饰的脂质化合物及其应用

Also Published As

Publication number Publication date
WO2010074935A1 (en) 2010-07-01
CN102325823A (zh) 2012-01-18
EP2370501A1 (en) 2011-10-05
JP2012513391A (ja) 2012-06-14
US8536375B2 (en) 2013-09-17
US20120004423A1 (en) 2012-01-05

Similar Documents

Publication Publication Date Title
JP4877225B2 (ja) ポリオキシアルキレン誘導体
AU2012301793A1 (en) Branched discrette PEG constructs
JP7063409B1 (ja) Ｆｍоｃ基を除去する方法
JPWO2017221889A1 (ja) 新規ジフェニルメタン保護剤
JP4012145B2 (ja) ピロール−イミダゾールポリアミドの固相合成法
JP5399422B2 (ja) 市販の安価な化学薬品からのｐｅｇ−６成分の合成
JPWO2019198834A1 (ja) リュープロレリンの製造方法
EP4247833A1 (en) Synthesis of prostate specific membrane antigen (psma) ligands
CN102325823B (zh) 得到改性聚乙二醇中间体的合成
JP7154513B1 (ja) 液相ペプチド製造方法
US20240018099A1 (en) Synthesis of prostate specific membrane antigen (psma) ligands
US9944750B2 (en) Polyethylene glycol substituted acyl borates
JP7658578B2 (ja) タンパク質及び／又はペプチド修飾用分子
JP2025001050A (ja) ガニレリクス又はその塩の製造法
RU2846888C2 (ru) Промежуточное соединение для синтеза fapi, способ его получения и применение
EP4247798B1 (en) Synthesis of prostate specific membrane antigen (psma) ligands
JP7522726B2 (ja) ピロールイミダゾール（ポリ）アミドの製造方法
JP2003508450A (ja) 分子のカップリング方法
JP5982720B2 (ja) 高分子固体状支持体を用いたヒスチジル−プロリンアミド誘導体の製造方法
WO2008105759A1 (en) Methods for synthesis of modified peptides

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C14 Grant of patent or utility model
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20140226

Termination date: 20141207

EXPY Termination of patent right or utility model